Summary of Novanta Incorporated Q2 2026 Earnings Call

1Key Financial Results and Metrics

Organic Sales Growth: 9% year-over-year; 10% reported growth.

Adjusted EBITDA Growth: 16% year-over-year, with an adjusted EBITDA margin of nearly 23%.

Adjusted Gross Margin: 47%, a 100 basis point improvement year-over-year.

Adjusted EPS: $0.89, up 17% from the previous year.

Operating Cash Flow: $65 million for Q2, exceeding the total for all of 2025; year-to-date operating cash flow reached $117 million.

Debt Metrics: Gross debt of $239 million, with a net debt position of negative $480 million.

2Strategic Updates and Business Highlights

Acquisition of Riverpoint Medical: Closed at the end of July, expected to be immediately accretive to revenue, gross margins, EBITDA margins, and earnings per share. This acquisition will double Novanta's recurring medical consumable business to approximately $300 million.

Innovation and New Products: New product revenue grew over 50% in the quarter, contributing to a vitality index of 29% of sales.

Manufacturing Strategy: Completed the closure of two factories and announced two additional closures by Q1 2027 to streamline operations and reduce costs.

Segment Performance:

Medical Solutions: Revenue grew 8.6% year-over-year, with strong performance in advanced surgery.

Automation Enabling Technologies: Revenue increased by 12%, driven by demand in robotics and AI applications.

3Forward Guidance and Outlook

2026 Revenue Guidance: Expected GAAP revenue of $1.13 billion to $1.14 billion, representing over 15% growth, with organic growth projected up to 7%.

Q3 2026 Guidance: Anticipated revenue of $300 million to $304 million, with organic growth of 7% to 9%.

Adjusted EBITDA for Q3: Expected between $74 million and $77 million, indicating a year-over-year increase of 27% to 33%.

Long-term Outlook: Positive trends in customer demand and backlog, with expectations for continued organic growth and margin improvements into 2027.

4Bad News, Challenges, or Points of Concern

Precision Medicine Segment: Expected to decline in Q3 due to challenges in the life sciences market, which is anticipated to remain below 10% of total revenue in 2026.

Operational Challenges: Higher costs associated with operational transformation and site rationalization may impact margins temporarily.

Tariff and Trade Issues: Continuing impacts from tariffs (Sections 232 and 301) may pose headwinds to gross margins.

Market Volatility: The macroeconomic environment remains complex, with potential risks from geopolitical factors.

5Notable Q&A Insights

Organic Growth Drivers: The Automation Enabling Technologies segment has shown improved performance, contributing to raised guidance.

Riverpoint Acquisition Impact: Expected to contribute approximately $35 million in revenue for Q3, with conservative estimates for the fourth quarter due to the transition to public company operations.

Advanced Surgery Business: Bookings are expected to strengthen in the back half of the year, despite some timing issues in Q2.

R&D Spending: Decreased to about 9% of sales, with expectations to rise slightly due to the inclusion of Riverpoint's R&D expenditures. In conclusion, Novanta's Q2 2026 results reflect strong organic growth and strategic advancements, particularly with the Riverpoint acquisition. However, challenges in specific segments and external market conditions warrant careful monitoring.